15530 Background: Basosquamous Cell Carcinoma (BSCC) of the larynx, hypopharynx and base of tongue represents 1% of all head and neck tumours. It is considered a more aggressive disease than squamous cell carcinoma, based on higher incidence of advanced stage disease (60% lymph node-involvement and 40% metastases at diagnosis). Therefore, a treatment regimen including chemotherapy is often recommended in addition to surgery and/or radiotherapy in the literature. Methods: We retrospectively analyzed the data of all patients diagnosed with BSCC of the head and neck at the University Hospital of Leuven between 1993 and 2003, and report here the stage at diagnosis, treatment modality, disease evolution, progression free and overall survival. Results: Seven patients where diagnosed with BSCC in the head and neck region. Six patients were male. Three of the tumours were localised in the larynx, two at the base of tongue, and two in the oral cavity. The AJCC stages of disease ranged from I to IVa. Three patients had lymph node involvement at diagnosis. Six patients were treated with surgery in combination with radiotherapy. One patient was treated with cryotherapy before brachytherapy was applied. Five patients have no evidence of disease with a follow up of 4, 5, 6, 10 and 11 years, respectively. One patient died of an unknown cause 18 months after treatment. Only one of the seven patients, developed metastases during follow up. This patient had BSCC of the base of tongue, and was diagnosed with lungmetastases 16 months after surgery and radiotherapy. He was treated with the combination of Doxorubicine, Cisplatin and Fluorouracil. A partial response was confirmed after six cycles. Eight months after the last treatment cycle, there is still no evidence of disease progression. Conclusions: BSCC is a rare tumour of the head and neck. Seven patients were treated at the University hospital of Leuven in the period between 1993 and 2003 with a median progression free and overall survival of more than 5 years. Only one patient developed metastases, and was consequently treated with chemotherapy, inducing a continuing partial remission 8 months after treatment. In contrast to what is reported in the literature we do not confirm a high incidence of metastases at diagnosis nor a high mortality rate. No significant financial relationships to disclose.